Welcome to our dedicated page for Pacific Software news (Ticker: $PFSF), a resource for investors and traders seeking the latest updates and insights on Pacific Software stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacific Software's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacific Software's position in the market.
Pacific Software has secured an exclusive licensing agreement with the University of California to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) for skincare and wound healing applications.
The technology, developed with over $6 million in research funding, will be spearheaded by Dr. Malcolm A. Leissring, who will become the Chief Science Officer of Pacific.
The IDE inhibitors, marketed as Dermatrix™, have shown significant capabilities in boosting collagen production, making them revolutionary for both wound healing and cosmetics. The agreement, effective as of March 5, 2024, also makes UC Regents an equity partner in Pacific.
Pacific Software Inc. (PFSF) announced the acquisition of certain assets from Dreamaderm Inc., including a patented cosmeceutical technology called Dermatrix. Dermatrix boosts collagen production by preserving insulin in the skin, offering a wide range of dermatological applications. The technology was developed by Dr. Malcolm A. Leissring and has the potential to revolutionize the cosmetics and skin care industry.
